Reshaping Medical Affairs: delivering value to KOLs and payers provides answers to pressing questions the industry is facing. This report includes primary research from within the pharmaceutical industry and related consulting.
Historically, the key role of Medical Affairs was supporting the initial regulatory approval. Today, that’s only the first hurdle. Due to increasing healthcare costs and the need to make difficult value-based decisions, the data package is extensive. Pharmaceutical companies must demonstrate the value of products through safety and efficacy trials, health economics trials and comparative efficacy trials, and medical affairs is taking on the bulk of the responsibility in providing that additional data package. (Source: FirstWord, August 2014).
